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Developing Biobanking Policy with an Oliver Twist:
Addressing the Needs of Orphan and Neglected
Diseases
[N]ow that he was enveloped in the old calico robes, which
had grown yellow in the same service, he was badged and
ticketed, and fell into his place at once . . . the orphan of a
workhouse-the humble half-starved drudge--to be cuffed and
buffeted through the world,-despised by all, and pitied by
none.
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INTRODUCTION
Centuries and an ocean removed from the life of a Dickensian
orphan, Megan Crowley was born in Massachusetts on December
16, 1996 to a loving family who showered her with affection.
According to her mother Aileen, "From the moment we held
Megan we knew she was special and that she would always be our
little princess. We had no idea at the time, however, just how
special or how brave Megan would become in so short a time.,
2
Megan, along with her younger brother Patrick, had been born
with a rare, hereditary muscular disorder, Pompe disease, which
degenerates muscle tissues and interferes with the respiratory and
cardiovascular systems. 3 The debilitating effects of Pompe make
even the most basic efforts impossible: Megan and Patrick cannot
"talk, swallow, walk, breathe or eat on their own." 4 While the
infantile-onset forms of the disease are often fatal before the first
year, 5 the two siblings have beaten the odds though they live with
2. Kristen Scarlatelli Dooley, A Race Against Time: Finding a Cure for
Pompe's Disease, Trinity Magazine (Spring 1999), http://www.trinitydc.edu/
newsevents/mags/spring99/pompe2.html (last visited Jan. 18, 2006).
3. Genzyme Corporation, Understanding Pompe Disease 1 (2002),
available at http://www.pompe.comglobal/pompe_brochure.pdf [hereinafter
Genzyme].
4. Barbara Laker, In Race Against Time, Dad Works To Find Cure,
Philadelphia Daily News, March 12, 2003.
5. Genzyme, supra note 3, at 6.
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twenty-four hour care and are closely monitored by a team of
doctors.
6
Pompe is considered an "orphan disease," one which affects
less than 200,000 individuals in the United States.7 While strides
have been made in developing enzyme replacement treatments for
Pompe, John Crowley, Megan and Patrick's father, works
tirelessly to find a cure--"Deep down, I know in five to 10 years,
no kid will ever suffer from this. If all I do in life is play some part
to find a cure, then that's OK.' ' 8 In fact, the first steps to finding a
cure for Pompe and a host of other diseases may lie with recent
developments in bioinformatics and biobanking.
9
As the tools of science and technology have improved
exponentially in recent decades, two of the leading fields,
information technology and genomics, have merged to form the
forefront of biomedical technology: bioinformatics. This
promising new field involves "a biological information processing
system-comprising computers, databases, on-line networking,
and specialized software-that has given birth to a new research
paradigm in which genotypic and phenotypic information is
'mined' to identify genes, to model protein structure, and to
discover drug targets." Advances in the field have "made it
possible to extract exponentially more information from any given
[genetic] sample and to process voluminous amounts of data."
This field has prompted demand for the creation of biobanks,
"large collections of human tissue samples . . . applying
6. Laker, supra note 4.
7. Genzyme, supra note 3, at 5. Orphan diseases are similar to neglected
diseases, that is, those diseases which are neglected because the costs of
developing therapies and cures cannot be justified because the market for these
medicines is too impoverished for those costs to be recouped. See generally
Drugs for Neglected Diseases Initiative, http://www.dndi.org/ (last visited Jan.
18, 2006). However, "orphan" seems to speak to the number of afflicted
patients while "neglected" indicates the proclivity of researchers to study the
disease, thus the two terms are not always coextensive though the Orphan Drug
Act encompasses both. 21 U.S.C.A. § 360ee(b)(2) (West 1999).
8. Laker, supra note 4.
9. See generally Matt Fleischer, Patent Thyself, The American Lawyer,
June 2001, available at 6/2001 Am. Law. 84 (a non-profit patient group, PXE
International, has utilized biobanking as a means of attracting research
attention).
10. David E. Winickoff, Governing Population Genomics: Law, Bioethics,
and Biopolitics in Three Case Studies, 43 Jurimetrics J. 187, 189 (2003).
11. Michael J. Malinowski, Technology Transfer in BioBanking: Credits,
Debits, and Population Health Futures, 33 J.L. Med. & Ethics 54, 56 (2005).
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'bioinformatics' to genomics research."' 12 These biobanks have
become a powerful tool to aid doctors and researchers in
"translat[ing] this rambling string of letters that constitute the
genome map into medical meaning.'
13
Because biobanks require large amounts of genetic samples as
research assets, these tissues have become inherently valuable, not
only to researchers but also to tissue donors from whom the
samples are obtained. Donors afflicted with diseases and
afflictions previously disregarded by mainstream researchers have
been dealt a powerful card in the form of their own tissues. If a
policy framework was established to promote altruistic biobanking
practices, donors may use their own tissues as leverage to acquire a
voice in pharmaceutical research and development efforts, steering
projects to target orphaned and neglected diseases.
However, while humanity may possess the scientific
wherewithal to pursue biobanking, a coherent policy framework to
encourage responsible and beneficial biobank development is
lacking. Indeed, it has been noted that, in general, biotechnology
"is likely to be an area of increasing importance, one in which both
public understanding and public policy lag well behind the rapid
advance of technological developments."' 14 Thus we are presented
with a unique opportunity to achieve previously unattainable health
policy objectives through incentives to encourage responsible
biobanking.
Incentives are necessary because market forces will likely drive
commercial pharmaceuticals to focus on diseases both dire and
profitable, an approach which leaves many other disease groups by
the wayside. 15 Thus policy, which has been developed to promote
the study of orphan and neglected diseases in industrialized
countries, could be expanded internationally to address similarly
situated diseases that also fall outside the realm of these
commercial interests.
This paper proposes a policy encouraging the development of
biobanks to aid in the research of neglected ailments and orphan
diseases. This policy would advance initiatives promoting the
organization of disease groups to stimulate research and raise
funds, as well as grant incentives similar to those offered by the
12. Winickoff, supra note 10, at 189.
13. Malinowski, supra note 11, at 56.
14. President's Council on Bioethics, Reproduction & Responsibility: The
Regulation of New Biotechnologies XL (2004), available at http://www.
bioethics.gov/reports/reproductionandresponsibility/_pcbe-final_
reproduction and-responsibility.pdf.
15. See discussion infra Part II.A.
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Orphan Drug Act, a Congressional enactment designed to
encourage development of treatments for "rare diseases and
conditions.'
16
Section I provides background on biobanking efforts, including
those championing the research of orphan and neglected diseases.
Section II discusses why some diseases will necessarily fall outside
the realm of commercial interest. Section III proposes policy
solutions and incentives which promote the development of
biobanks and encourage research of neglected ailments.
I. BIOBANKING EFFORTS DOMESTICALLY AND ABROAD
Biobanks provide the means to process voluminous amounts of
genetic samples and corresponding medical data, weaving a
complete genotypical and phenotypical snapshot of a sampled
population and creating an essential resource for researchers.
However, many previous biobanking efforts are no longer useful
due to the failure of organizers to collect medical records and
obtain adequate informed consent from donors in order to ethically
broaden the field of research objectives for which donated tissues
may be used. 17 Coupled with trends in biomedical science, the
demand for new biobanks has been greatly enhanced. The
accompanying call for genetic and medical information to fill these
biobanks has never been greater.18 The most widely implemented
biobanks, unprecedented in the number of donor samples they
collect, are primarily governmental, commercial-governmental, or
commercial-academic collaborations that promise little, if any,
return for the efforts of their volunteers. 19
16. 21 U.S.C.A. § 360ee(a) (West 1999).
17. E.g., Malinowski, supra note 11, at 56; Winickoff, supra note 10, at
193.
18. E.g., Malinowski, supra note 11, at 56; Fleischer, supra note 9.
19. The UK Biobank is largely a governmental project with contributions
by non-profit organizations while the Estonian Genome Project is solely a
government effort. See generally UK Biobank, http://www.ukbiobank.ac.uk/
(last visited Jan. 18, 2006); Estonian Genome Project, http://www.geeni
varamu.ee/ (last visited Jan. 18, 2006). Iceland is developing a national biobank
in cooperation with deCODE, a for-profit corporation. See generally deCODE
Genetics, http://www.decode.com/ (last visited Jan. 18, 2006). Ardais, a for-
profit corporation is a key player in the National Clinical Genomics Initiative
which matches it with leading medical institutions in the United States. See
generally Ardais Corporation, http://www.ardais.com (last visited Jan. 18,
2006).
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By contrast, disease groups previously left out of the genomics
revolution have initiated grassroots efforts using biobanks as a
means to leverage the value of their own genetic samples and
medical records. These efforts have stimulated research that
promises tangible returns for donors by isolating theogenes which
cause the disorder and leading to possible treatments.
England's UK Biobank is one of the world's flagship
initiatives with up to half a million projected participants between
the ages of forty-five and sixty-nine. It is, by far, the largest
biobanking organization with plans to include about 500,000
participants z.2  This is unsurprising given its considerable support:
among its backers include British governmental entities such as
UK Medical Research and the Department of Health, as well as the
Wellcome Trust, a biomedical research charity organization. The
UK Biobank hopes to correlate urine and blood samples with
lifestyle data to achieve "a greater understanding of genetic,
lifestyle and environmental factors in health and disease .... 22
Similarly, the wholly governmental Estonian Genome Project
has cataloged 10,000 samples to date with the aim of making "it
possible to carry out research both in Estonia and outside to find
20. Press Release, PXE International, U.S. Patent Office Issues First Gene
Patent to Patient Advocacy Group; Co-Inventors Include Non-scientist "Mom"
(Aug. 24, 2004), available at http://www.pxe.org/patent.html (last visited Jan.
18, 2006).
21. Press Release, UK Biobank, Statement from Chair of Board of Directors
on Chief Executive Officer Transition Arrangements (Jan. 14, 2005), available
at http://www.ukbiobank.ac.uk/news/pr/14jan05.php (last visited Jan. 18, 2006).
The UK Biobank notes that it "will be the world's biggest resource for the study
of the role of nature and nurture in health and disease" and "[uip to half a
million participants aged between 45 and 69 years will be involved in the
project." Id. Comparable efforts in Estonia have cataloged 10,000 samples.
Estonian Genome Project, http:llwww.geenivaramu.ee/index.php?lang=eng&
sub=58 (last visited Jan. 18, 2006). More than 100,000 volunteers have agreed
to provide samples to deCODE's biobank in Iceland. deCODE Genetics, From
Genes to Drugs, http://www.decode.com/ main/view.jsp?branch=164430 (last
visited Jan. 18, 2006). Howard University's biobank, a means to help
researchers target diseases that predominantly affect peoples of African descent,
hopes to "gather the genetic codes, along with personal and family health histories,
of about 25,000 people." Melissa Healy, Genetic Researchers: Race Isn't a
Black and White Issue, Miami Herald, Oct. 14, 2003, available at 2003 WLNR
6187453.
22. UK Biobank, UK Biobank Briefing Note-April 2004 2, available at
http://www.ukbiobank.ac.uk/docslong-briefing-paper.pdf (last visited Jan. 18,
2006).
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links between genes, environmental factors and common diseases...
and to apply the information gained from research in making new
discoveries in genomics and epidemiology 3 which eventually lead
to increasing the efficiency of health care.
While Iceland has joined England and Estonia in the
biobanking field, it has done so with commercial considerations
expressly in mind, having partnered with deCODE Genetics, a
private, Reykjavik-based biopharmaceutical company. As of mid-
2003, the Icelandic project has cataloged medical records and
genetic tissue from almost 100,000 people, or almost half of the
nation's adult population. The aim of deCODE is:
to identify the genetic causes of common diseases and to
apply this information to develop new drugs and diagnostic
tools. Built upon an understanding of the basic biology of
human disease, these products are aimed at diagnosing and
counteracting the underlying biological mechanisms of
disease, not just the signs and symptoms. 24
Teaching hospitals, including Beth Israel Deaconess Medical
Center, Duke University Medical Center, the Maine Medical
Center, and the University of Chicago, are also collaborating with
commercial interests in cataloging donor tissue and medical data.
25
As part of the National Clinical Genomics Initiative, these teaching
hospitals obtain tissue samples and medical information from
patients. 26 Each hospital treats this data as its own property and
licenses its use to Ardais Corporation. 272 8 In exchange, Ardais
grants each hospital a share of its revenue. Ardais then uses this
data to "develop systematic, large-scale procedures to
comprehensively collect, process, and store research-quality
clinical materials and associated information; to provide these
critical resources in highly optimized formats for efficient and
robust design of biomedical research studies; and to support the
research and clinical programs at each participating medical
institution., 29
23. Estonian Genome Project, supra note 21.
24. deCODE Genetics, The deCODE Population Approach, http://www.
decode.com/main/view.jsp?branch=31214 (last visited Jan. 21, 2005).
25. Ardais Corporation, Overview, http://www.ardais.comldonoroverview
.asp [hereinafter Ardais Overview] (last visited Jan. 31, 2005).
26. Id.
27. Winickoff, supra note 10, at 208.
28. Id.
29. Ardais Overview, supra note 25.
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Howard University is also developing a prominent academic
biobanking venture. Howard hopes to provide researchers with an
invaluable tool to help "solve the enduring medical mystery: why
black Americans seem to fall ill with so many
diseases-hypertension, heart disease, prostate and breast cancer,
asthma, glaucoma and obesity---more frequently than do white
Americans and most major ethnic groups in the United States." 30
Howard hopes to include approximately 25,000 participants in its
effort.3
Given the broad mandates of these projects, the immense
number of donors involved, and their sometimes overt commercial
ambitions, it is perhaps unsurprising that participation in these
initiatives typically grants tissue donors little direct benefit despite
the invaluable contributions they make. For example, the Estonian
project expressly relinquishes any donor interest in any subsequent
discoveries, 32 as does the UK Biobank, 33 the Iceland-deCODE
biobanking effort,34  and the National Clinical Genomics
Initiative. Howard University's project may be a notable
exception as it promises to aid researchers interested in diseases
which plague the racial group of its donors.
As many of these efforts divest their donors of any interest in
their own tissues, they simultaneously move toward methods of
30. Healy, supra note 21.
31. Id.
32. Estonian Genome Project, Gene Donor Consent Form (2001), available
at http://www.geenivaramu.ee/index.php?lang=eng&sub=74 (last visited Jan.
18, 2006) ("I may not request a fee for providing a tissue sample .... The right of
ownership of the tissue sample, of the description of my state of health and of other
personal data and genealogy shall be transferred to the Estonian Genome Project
Foundation.").
33. UK Biobank, Your Questions Answered, http://www.ukbiobank.ac.uk/
about/faqs.php [hereinafter UK FAQ] (last visited Jan. 18, 2006) ("As with the
majority of charity and public-sector research, participants will not be paid for taking
part in the project.... UK Biobank will be the legal owner of the database and the
sample collection. Participants will not have property rights in the samples and this
will be explained at the outset before they consent to participate.").
34. deCODE Genetics, Information for Participation in a Genetic Study of
[Name of Disease], http://www.decode.com/files/filemanager/websitel/file148517
.pdf [hereinafter deCODE Consent Form] (last visited Jan. 18, 2006) ("If you decide to
take part in the study, you have to relinquish any claims to such financial gains ....").
35. Winickoff, supra note 10, at 216 ("The [Beth Israel] consent form states
that 'there will be no direct benefit' to participants in the program, but that
'society may benefit from research using your tissue by learning more about
what causes diseases, how to prevent them, how to treat them, and how to cure
them."' (citing the Ardais-Beth Israel consent form)).
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commercially exploiting these assets. For instance, UK Biobank
acknowledges potential collaboration with commercial interests.
36
However, as Howard University's model indicates, donor
interests do not always have to be swept away by the drive to
commercialize. A smaller scale biobanking effort, PXE
International, organized by an orphan disease group, has leveraged
the value of donor materials to acquire tangible results and
treatments for those who contribute.
PXE International is a non-profit organization formed to
address the needs of those afflicted with the orphan disease
pseudoxanthoma elasticum ("PXE"), a rare connective tissue
disorder. 37 Founded by the parents of children afflicted by this
disease, PXE International has acquired over a thousand samples
and has achieved some level of success by granting access only to
researchers studying and developing therapies for PXE.38 Thus,
PXE International has harnessed the value of its members' own
biological material and used it to directly benefit those donors.
This result is remarkable not only because it is able to
meaningfully reward donor contributions, a result its fellow
ventures have been unable to achieve, but most importantly
because this reward empowers an otherwise disenfranchised
disease group. The PXE International approach as a model for
biobanking by patient groups is discussed more thoroughly in Part 1IH.
II. AN EMBARRASSMENT OF RICHES: FEAST AND FAMINE IN THE
GLOBAL HEALTH TRADE
The health revolution of the last 30 years, which has
produced substantial gains in life expectancy and
unparalleled medical advances, has left most of the world's
population behind in important ways . . . . For these
36. UK FAQ, supra note 33 ("Will pharmaceutical companies be able to
access the information? Yes. It is important that pharmaceutical companies can
access the information in order to research potential new drugs and
treatments.").
37. Genetics Home Reference, Pseudoxanthoma Elasticum, http://ghr.nlm
.nih.gov/condition=pseudoxanthomaelasticum (last visited Nov. 2005).
38. Winickoff, supra note 10, at 224 ("PXE International has been
extremely successful at attracting collaborating research groups, and there are
now 17 laboratories in the PXE research consortium.").
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people, the imbalance between their needs and the
availability of medicines is fatal.39
Biobanks are a means to help researchers address innumerable
diseases. However, commercial biobanks will, by necessity of
both market opportunities and restraints, focus their studies on
diseases afflicting relatively large, affluent populations to realize a
profit or at least recoup research expenditures.4 ° Without a clear
public policy mandate to address neglected diseases, it is likely
public institutions will follow the lead set by commercial efforts
blunting another avenue for addressing neglected diseases.
4 1
Similarly, though some orphan diseases in the United States have
attracted a meaningful measure of commercial attention with the
help of legislation, many other diseases remain unaddressed. A
coherent public policy mandate must encourage the development
of biobanking resources to aid the study of neglected and orphan
diseases, particularly abroad. Not only would such a policy
encourage the practice of biobanking itself among populations left
out of the genomics revolution, but the very existence of these
biobanks could act as an incentive to stimulate further research of
treatments and perhaps even cures for these diseases.
39. M6decins Sans Fronti~res, Fatal Imbalance: The Crisis in Research and
Development for Drugs for Neglected Diseases 8 (2001) [hereinafter Fatal
Imbalance].
40. Ken Silverstein, Millions for Viagra, Pennies for Diseases of the Poor,
The Nation, (July 19, 1999) available at http://www.thenation.com/
doc.mhtml?i=19990719&s=silverstein ("'A corporation with stockholders can't
stoke up a laboratory that will focus on Third World diseases, because it will go
broke,' says Roy Vagelos, the former head of Merck. 'That's a social problem,
and industry shouldn't be expected to solve it."') ("As Neil Sweig, an industry
analyst at Southeast Research Partners, puts it wearily, 'It's not worth the effort
or the while of the large pharmaceutical companies to get involved in
enormously expensive research to conquer the Anopheles mosquito."').
41. Fatal Imbalance, supra note 39, at 20 ("[P]ublic sector research has
increasingly focused on diseases that affect wealthy countries. There is
increasing pressure for publicly funded research to have commercial
applications, further reinforcing the focus on lucrative diseases .... [P]ublic
sector policies increasingly view public research as an investment that needs to
create economic value.").
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A. "One Pill Makes You Larger and One Pill Makes You
Small: "42 Abandoning Neglected Diseases and Developing
Lifestyle Drugs to Satisfy the Whims of the Market
In the past, while commercial research has headed off many
potentially fatal conditions, 43 these efforts have also launched a
surfeit of comparatively trivial "lifestyle" treatments targeting such
ills as baldness, erectile disfunction, and wrinkles. 44 Indeed, these
lifestyle drugs pursue a lucrative market; Viagra accounted for
more than $1 billion in sales for Pfizer in 200345 while Botox, a
treatment for facial wrinkles, has garnered its manufacturer,
Allergan, more than $325 million in sales in the first half of 2004
alone.46 As a point of reference, drugs with annual sales of more
than $1 billion are considered "blockbusters. 47
Commercial ventures can hardly be blamed for seeking out
these lucrative lifestyle markets. With rising research and
development costs48 these few blockbusters not only sustain
42. Jefferson Airplane, White Rabbit (Go Ask Alice), on Surrealistic Pillow
(RCA 2003).
43. Pfizer's Glucotrol treats diabetes, Inspra treats high blood pressure and
congestive heart failure, and Neurontin treats epilepsy. Merck's Zocor
addresses high cholesterol and Cozaar treats hypertension.
44. Baldness treatments include Pfizer's Rogaine and Merck's Propecia.
Erectile disfunction treatments include Pfizer's Viagra, Lilly ICOS' Cialis, and
Bayer and GlaxoSmithKline's Levitra. Wrinkle treatments include Allergan's
Botox, Q-Med's Restylane, and Inamed's Hylaform.
45. Pfizer Inc., Annual Report Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934 for the Fiscal Year Ended December 31, 2003
15 (2004), available at http://www.pfizer.com/pfizer/download/investors/
financial/ 10k_0310_04.pdf.
46. Business Wire, Allergan Reports First Quarter Operating Results (April
30, 2004), available at http://www.shareholder.com/AGN/ReleaseDetail.cfm?
ReleaselD=134256 (reporting $150.7 million in Botox sales for the first quarter
of 2004). Business Wire, Allergan Reports Second Quarter Operating Results
(July 28, 2004), available at http://www.shareholder.comAGN/Release
Detail.cfm?ReleaselD=140466 (reporting $176.9 million in Botox sales for the
second quarter of 2004).
47. Fei Mei Chan, Potential Blockbuster Drugs, Forbes, October 8, 2003,
available at http://www.forbes.comI/2003/10/08/cz_fmc_1008sf.html.
48. Estimates of expenditures vary significantly as few industry sources are
willing to comment on research costs. Studies have placed typical research and
development costs anywhere between $110 and $800 million. See Fatal
Imbalance, supra note 39, at 17 ("The group Public Citizen ... computes the
cash outlay for new drugs at $110 million"); Drug Store News, Turbulent Future
Awaits Pharmaceuticals, March 23, 2003, available at http://www.
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pharmaceutical companies, but compensate for less profitable
ventures as well.49 Sales of these blockbuster lifestyle drugs also
counterbalance the financial risks which remain even after a drug
has entered the market. For instance, subsequent testing of FDA-
approved pharmaceuticals may show that a drug has unacceptable
side effects, requiring an expensive withdrawal from the market
which may also involve protracted litigation.50 Moreover, many of
findarticles.com/p/articles/mim3374/is_4_25/ai_99309279 "Currently, Frost &
Sullivan analysts tag the average cost of bringing a new drug to market at $800
million."). Even ostensibly reliable sources may manifest significant bias. See
Silverstein, supra note 40 ("The drug companies defend their extraordinary
profit margins, and their neglect of tropical disease, by pointing to the risks and
costs of R&D .... [T]he costs run to an average of about $500 million per new
drug .... Many public health activists believe the number is wildly inflated.
PhRMA gets the $500 million figure by extrapolating from a controversial 1987
Tufts University study that factored in such variables as 'opportunity
costs'--i.e., the amount of money companies forgo by not investing their R&D
funds in, say, thea stock market-pegged to an outrageous 9 percent rate of
inflation. One of the chief researchers on the Tufts study... has been heavily
subsidized by the industry.").
49. Merck's Emend, which lessens the side effects of chemotherapy,
accounted for a relatively meager $15 million in sales for the first half of 2004.
See Merck & Co. Inc, Other Financial Disclosures First Quarter 2004 1 (2004),
available at http://www.merck.com/newsroon/pdf/lq04_otherfinancialdis
closures.pdf (reporting Emend sales of $6 million in the first quarter); Merck &
Co. Inc, Other Financial Disclosures Second Quarter 2004 1 (2004), available at
http://www.merck.com/newsroom/pdf/2q04_other-financialdisclosures.pdf
(reporting Emend sales of $9 million in the second quarter). Pfizer's Caduet,
which reduces LDL cholesterol and hypertension, garnered $30 million in sales
in the first six months of 2004. Pfizer Inc., Quarterly Report Pursuant to Section
13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period
Ended June 27, 2004 25 (2004), available at http://www.pfizer.com/
pfizer/download/ investors/financial/10q_0806O04.pdf.
50. Merck's Vioxx, which treated arthritis pain, was withdrawn from the
market after a three year clinical study demonstrated it doubled the risk of heart
attack and strokes. Vioxx accounted for $2.5 billion in worldwide sales for
Merck in 2003 and the company was expected "to take a charge of $700 million
to $750 million in the second half of this year to cover the costs of withdrawing
Vioxx, including customer returns of pills sold, lost future sales and writing off
the value assigned to inventory." Milt Freudenheim, Merck and Vioxx: The
Company; A Blow to Efforts to Close In on Rivals, N.Y. Times, Oct. 1, 2004,
Cl, available at 2004 WLNR 4778737. These estimates do not account for the
costs of defending Vioxx-related lawsuits. Consider an Illinois class action suit
which includes all Vioxx users in the state, numbering around 300,000
COMMENTS
these lifestyle drugs are byproducts of research into genuinely life-
threatening conditions.5'
Nevertheless, both impoverished and small disease populations
are overlooked because active investment in these groups would
not be commercially sound; economic forces favor targeting the
afflictions of large and wealthy populations. 52  These market
constraints prevent commercial efforts from entering realms where
they would do the most good, especially in third world countries
where, for instance, an estimated one million people die of malaria
each year.
53
individuals. The only named plaintiff, Constance Oswald, filed suit even though
Vioxx relieved osteoarthritis pain in her knees and feet: "My experience with
Vioxx was great; it really helped me." Lori Rackl, Illinoisans Join Parade of
Suits Against Merck Over Vioxx, Chicago Sun-Times, Oct. 5, 2004, available at
2004 WLNR 11725883. The costs of withdrawing Vioxx from the market and a
recent jury verdict have both taken a significant financial toll on Merck. Since
Merck has stopped selling Vioxx, "its stock has fallen almost 40 percent, cutting
nearly $40 billion from the company's market value." Alex Berenson, Second
Trial For Merck On Vioxx Begins, N.Y. Times, Sept. 15, 2005, C1, available at
2005 WLNR 14523966. In August 2005, an Angleton, Texas jury ordered the
pharmaceutical company to pay a plaintiff, whose husband died after taking
Vioxx for eight months, $253 million-though Texas law will automatically
reduce the recovery to $26 million. Id. Moreover, litigation is far from over as
"5,000 people have already sued Merck," and lawyers expect "at least 25,000
suits to be filed eventually." Id. Not surprisingly, the potential cost of these
lawsuits is enormous as "[a]nalysts have estimated that Merck, the third-largest
American drug maker, could eventually be forced to pay as much as $50 billion
to settle Vioxx lawsuits if juries continue to rule against it." Id.
51. Managed Care, Q & A with Alan F. Holmer, Pharmaceutical Research
and Manufacturers of America (PhRMA), Terms of Coverage for Elderly Top
Priority for Drug Industry, April 2001, available at http://www.managed
caremag.com/archives/0104/0104.qna-holmer.html ("Most current so-called
'lifestyle drugs' were discovered while testing a medicine for a life-threatening
disease. For example, a medicine that stimulates hair growth in men was
discovered during the testing of a drug that was intended to treat prostate
disease. The vast bulk of research dollars spent by pharmaceutical companies
are directed toward life-threatening conditions.").
52. Silverstein, supra note 40.
53. Roll Back Malaria, Malaria in Africa, http://www.rbm.who.int/cmc_
upload/0/000/015/370/RBMInfosheet_3.htm (last visited Jan. 18, 2006) ("There
are at least 300 million acute cases of malaria each year globally, resulting in
more than a million deaths. Around 90% of these deaths occur in Africa, mostly
in young children. Malaria is Africa's leading cause of under-five mortality
(20%) and constitutes 10% of the continent's overall disease burden. It accounts
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This market failure has been exacerbated by failures of public
policy.54 The resulting data on drugs targeting neglected diseases
is startling; in the last twenty-five years, 179 new drugs were
developed for cardiovascular diseases accounting for eleven
percent of the global disease burden.55 In the same period, just
fifteen new drugs were developed to treat tropical diseases and
tuberculosis, diseases representing twelve percent of the global
disease burden. 56  Only a meager portion of the seventy billion
dollars57 spent globally each year on research and development is
devoted to these neglected diseases.58 This disparity has resulted
in the charge that ninety percent of health research resources have
been devoted to just ten percent of the population, the so-called
"10/90 gap" in health research 59 with undue focus given to
lucrative markets such as North America, Japan, and Europe.
60
for 40% of public health expenditure, 30-50% of inpatient admissions, and up to
50% of outpatient visits in areas with high malaria transmission.").
54. Fatal Imbalance, supra note 39, at 10-11, 20. ("This failure does not
rest exclusively on the shoulders of the private sector. Governments hold the
ultimate responsibility for ensuring that peoples' basic health needs are met.
They have the responsibility to take appropriate action when market forces fail
to address these needs. In the past few decades, despite clear evidence of
waning private sector interest in the diseases of the poor, government action has
been inadequate .... A needs-based approach and consolidated public funding
of R&D for neglected disease drugs could have compensated for the market
failure. Instead, public sector research has increasingly focused on diseases that
affect wealthy countries. There is increasing pressure for publicly funded
research to have commercial applications, further reinforcing the focus on
lucrative diseases.")
55. Fatal Imbalance, supra note 39, at 10. "Disease burden" expresses the
burden imposed on a population due to death and disability. World Health
Organization, Quantifying Environmental Health Impacts, available at
http://www.who.int/quantifying-ehimpacts/en/ (last visited Jan. 18, 2006).
56. Fatal Imbalance, supra note 39, at 10.
57. Id. at 16.
58. "Little more than US$100 million per year" accounts for
public/nonprofit/foundational spending. Id. at 21. In a survey of eleven
pharmaceutical companies, where six of the top ten were represented, most
reported spending less than 1% on the neglected diseases surveyed and only one
noted that it "devoted over 15% of its infectious disease R&D budget to
tuberculosis and malaria." Id. at 12.
59. See generally the Global Forum for Health Research: Helping Correct
the 10/90 Gap, http://www.globalforumhealth.org/ (last visited Jan. 18, 2006).
60. Fatal Imbalance, supra note 39, at 16.
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Indeed, statements by the pharmaceutical industry indicate there is
merit to this assertion.
61
B. "Please Sir, I Want Some More: " 62 The Orphan Drug Act-A
Not-Quite-Perfect Solution to Address the Famine
While the situation of most neglected diseases is dire, the status
of some orphan diseases is not quite as desperate. The condition of
orphan disease populations in industrialized nations, particularly in
the United States, is improving though far from ideal.
1. The Orphan Drug Act 6 in the United States
The Orphan Drug Act 64 was passed in 1983 to address "rare
diseases and conditions" which affect "less than 200,000 persons"
in the U.S. or "affects more than 200,000 in the [U.S.] and for
which there is no reasonable expectation that the cost of
developing [the dru will be recovered from sales in the United
States of such drug.
The committee report considering passage of the act believed
that "many more drugs for rare diseases can be developed if
private drug companies become more actively involved.",66 This
involvement was absent because "there [was] no governmental
61. Id. at 18. Fred Hassan, who was Chief Executive Officer of Pharmacia
Corporation at the time, noted,
[Tihe United States has become the must-win market for every
pharmaceutical company. In addition, there are just six or seven other
critical markets, including Japan and key countries in Europe .... This
does not mean ignoring other markets. But it does mean strategically
concentrating resources and top management attention on success in the
key market. Again, this is very different from our industry's approach
in the past, which focused on therapeutic areas across geographical
regions.
62. Dickens, supra note 1, at 14.
63. Intuitively, allocating significant research funds towards diseases which,
by definition, do not affect large populations may seem inefficient. However,
these expenditures are worthwhile, not only from a humanitarian standpoint but
also because research into rare diseases often leads to treatments and cures for
more common ailments. Carol Rados, Orphan Products: Hope for People With
Rare Diseases, FDA Consumer Magazine, (November-December 2003),
available at http://www.fda.gov/fdac/features/2003/603_orphan.html (last
visited Jan. 18, 2006).
64. 21 U.S.C.A. § 360aa, 360ee (West 1999).
65. Id. § 360ee(b)(2). See discussion supra note 7.
66. H.R. Rep. No. 97-840(I), at 7 (1982).
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policy and therefore no governmental mechanism, to facilitate the
development of ... drugs or vaccines . . .for which the market
offers no financial reward. 67 To rectify this situation, the Orphan
Drug Act sought to change "applicable federal laws to reduce the
costs of developing drugs for rare diseases and to provide
financial incentives for their development"'68 which includes
research grants, tax credits, and a seven year period of marketing
exclusivity.6
9
These incentives have been very effective: in the ten years
before the Act was passed in 1983, just ten treatments had been
developed to address orphan diseases. 70  By 2003, the Orphan
Drug Act had encouraged development of more than 1,100
treatments for orphan diseases with 250 approved for use in the
United States.7' It has been estimated that more than twelve
million patients have received drugs that would otherwise not have
been developed without the Orphan Drug Act.72  Moreover,
orphaned populations often benefit from strong, grassroots
organizations such as PXE International and the Genetic Alliance
which promote patient advocacy in public forums.7 3
However, the Orphan Drug Act which has spurred these
changes is far from perfect. Though the Act has stimulated
significant drug development for orphan diseases, granting orphan
status to more than 900 ailments, 74 many orphan diseases still have
67. Id. at 6.
68. Id. at 7.
69. Food and Drug Administration, OOPD Program Overview,
http://www.fda.gov/orphanprogovw.htm (last visited Jan. 18, 2006).
70. National Organization for Rare Diseases, Inc., Annual Report 2003 4
(2003).
71. Id. This surfeit of therapies induced by the relatively modest incentives
granted by the Orphan Drug Act implies that the demands of research and
development may not be as onerous as pharmaceutical companies suggest-
viable therapies may be developed for significantly less than $800 million. See
discussion supra note 48.
72. Larry Stevens, Orphan Drug Act at 20: Big Gains, Some Strains,
American Medical News (August 4, 2003), available at http://www.ama-
assn.org/amednews/2003/08/04/gvsa0804.htm.
73. See generally PXE International, www.pxe.org; Genetic Alliance,
www.geneticalliance.org.
74. John Henkle, Orphan Drug Law Matures into Medical Mainstay, FDA
Consumer (May-June 1999), available at http://www.fda.gov/fdac/features/
1999/399_orph.html (last visited Jan. 18, 2006).
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no effective therapies. 75  Even those that have been developed
"play a very modest role in helping sufferers of rare disorders." 76
In one instance, a drug developed to treat ALS, Lou Gehrig's
disease, "can extend the life of ALS patients by only about three
months."
77
Also, adequate funding remains an issue. The Food and Drug
Administration, in fiscal year 2004, awarded about thirteen million
78dollars in grants to Orphan disease research. Phase I studies are
eligible for $150,000 of funding per year while Phase HI and III
studies may receive $300,000 per year. 79  However, "while the
amount of funding has remained level, it's eroded each year by
inflation and increased need" and in an environment where
commercial pharmaceuticals are spending hundreds of millions on
research and development each year, "[o]ne hundred and fifty-
thousand dollars doesn't go far when it comes to drug research."V
2. Orphan Drug Acts Internationally
The Orphan Drug Act has spurred similar legislation
internationally, often with mixed results. 8 For instance, the
European Union ("EU") enactment is similar to that of the United
States' with provisions for, among other incentives, research
grants, reduction of marketing fees, and a period of market
75. Stevens, supra note 72 ("Although the act has spawned 231 drugs, many
orphan disorders still have no effective therapies.").
76. Id.
77. Id.
78. Food and Drug Administration, OOPD Frequently Asked Questions,
http://www.fda.gov/orphan/faq/index.htm (last visited Jan. 18, 2006) ("The
current annual budget for funding grants is approximately $13 million.");
Thomas Morrow, Orphan Drug Act Treatments Deserve Full Insurance
Coverage, September 2004, http://www.managedcaremag.com/archives/0409/
0409.biotech.html ("In fiscal year 2004, the FDA awarded a total of $13.3
million in grants.").
79. Morrow, supra note 78.
80. Stevens, supra note 72.
81. Obesity, Fitness & Wellness Week, Incentives Available for Developing
Treatments for Inborn Errors, available at 2004 WLNR 681337 ('The success
of this legislation was a factor leading to the 1993 orphan drug law in Japan; the
1997 implementation... in Australia; and, in 1999... in the European Union
(EU)," stated Haffner. "Today, international support for rare disease research is
providing stimulus and motivation to overcome the financial barriers and
encourage development of treatment for very rare diseases throughout the
world.").
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exclusivity of ten years, three years longer than its American
equivalent. 2
However, the EU's orphan drug act has come under fire
because "150 medicines have been formally designated as of
special value by the scheme, [though] so far just 11 of these
products have received a marketing authorization and are available
to patients." 83 According to a group of European biotechnology
firms, this impasse is because of:
"a lack of . . . coherence in the policies applied by the
different regulatory and national authorities--during the
long process from research bench . . . to the patients'
bedside." Above all . . . there is a need to speed up the
granting of marketing authorisations and to ensure
availability and affordability of novel treatments.
84
Japan's orphan drug law was also drafted with an eye toward
its American counterpart and offers similar benefits to researchers:
funding grants, tax reductions, priority placement on the regulatory
body's examination schedule, and ten years of marketing
exclusivity.85  However, the Japanese law differs from its
American and European counterparts in pricing and accessibility.
Like its counterparts, the Japanese orphan drug enactment is
not perfect. Commentators have noted that the "U.S. system
already contains many buffers against potential harms due to
exorbitant prices," and "while the price of U.S. orphan drugs is
high [despite these buffers], the price of Japanese orphan drugs is
much greater.. . often two or three times that of the U.S. price." 
86
But "since the medical coverage for Japanese citizens includes
prescription drugs, the higher prices are spread over the entire
nation." 87  While sweeping changes to prescription drug cost
structures would undoubtedly prove unwieldy and controversial,
this approach to medical coverage may resolve issues of orphan
82. European Agency for the Evaluation of Medicinal Products, Orphan
Medicinal Product Designation in the European Union 2, http://www.emea.eu.i
nt/pdfs/human/comp/leaflet/661801En.pdf (last visited Jan. 18, 2006).
83. Europe Information Service, Biotech Firms Seek Better Conditions,
http://www.ebe-efpia.orgaboutebe/inpress/pdf/250603eis.pdf (last visited Jan.
15, 2006).
84. Id.
85. Gina M. Cavalier, Pushing Parentless Pharmaceuticals: Toward an
International Home for "Orphan Drugs" and a Cure for "Zebra" Diseases, 27
Law and Pol'y Int'l Bus. 447, 450-51 (1996).
86. Id. at 458.
87. Id.
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drug affordability in both the United States and the European
Union.
Even with these various orphan drug acts, the situation of
orphan disease groups remains less than ideal. The status of
neglected disease groups, especially in impoverished nations, is
critical; the development of biobanks may be the first step to
ushering in many new therapies for these illnesses.
Yet, there is little indication that the market constraints which
have impeded research on orphan and neglected diseases in the
past can be transcended by the mere introduction of new
technology. Commercial interests will likely continue to employ
88new technological means for ends similar to the old. Thus it
seems prudent to leave commercial biobanking efforts to their own
devices while asserting national and international policy to
encourage small and impoverished populations to create biobanks
that may attract academics and even previously uninterested
commercial researchers.
III. INITIATIVES TO ADDRESS NEGLECTED AND ORPHANED
DISEASES
The enjoyment of the highest attainable standard of health
is one of the fundamental rights of every human being
without distinction of race religion, political belief
economic or social condition.9
Developing a more charitable biobanking policy does not
necessitate substantial subsidies or gratuitous donations; significant
progress does not hinge on charitable giving per se. While
conventional stimuli such as tax incentives and research grants
would promote biobanking research, the biobanking concept
already grants an asset to small and impoverished disease groups
by rendering, their medical data and genetic samples valuable to
researchers." Thus, while biobanking itself may not drastically
88. See Rebecca J. Morris et al., Capturing and Profiling Adult Hair
Follicle Stem Cells, Nature Biotechnology 411-17 (April 22, 2004), available at
http://www.nature.com/nbt/joumal/v22/n4/full/nbt950.html (last visited Jan. 18,
2006); Jennifer Warner, Stem Cells Can Regrow Hair, WebMD, March 15,
2004, http://aolsvc.health.webmd.aol.com/content/article/83/97894.htm (last
visited Jan. 18, 2006).
89. The World Health Organization (WHO) Const. pmbl. [hereinafter WHO
Constitution].
90. According to Professor Malinowski, "biobanking is a means for groups
traditionally excluded from biomedical R&D to inspire research on their
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reduce the cost of pharmaceutical research and development,91 it
nevertheless allows patient groups to cultivate a portfolio of
valuable assets including medical and genetic data, and even gene
patents. The groups are then able to direct the costs by negotiating
with those most willing to pay: commercial and academic interests
eager to gain access to their biobanks and patent assets.
To this end, policy initiatives must encourage the organization
of these groups left out of the genomics revolution to maximize
their biological assets and political clout to attract research interest.
Cues may be taken from the technology transfer research and
development experience to help organize patients afflicted with
orphaned and neglected diseases to maximize biobanking assets.92
In cases where self-promotion fails or requires additional
assistance, governmental entities could provide incentives to
induce research similar to those offered by the Orphan Drug Act.
The groups most likely to benefit from these initiatives may be
orphan disease groups in industrialized nations and neglected
diseases groups in impoverished areas. In these instances, PXE
International's efforts may pose the archetype for future
biobanking efforts organized by patient groups.
Guided by patients and the relatives of patients, those with the
largest stake in finding therapies and cures, PXE International
recruits researchers who contract on the non-profit organization's
terms. These researchers must "sign a contract giving PXE
International co-ownership of any patent that ensues from study of
their tissues '93 and the organization's stewardship over its closely
held biological portfolio has yielded significant success. In 2000,
four years after PXE International was incorporated, collaborating
researchers at the University of Hawaii were able to isolate the
PXE gene.94 With the assistance of pro bono counsel and a war
ailments, and to do so on their terms-meaning with thoughtful, negotiated, and
sound contractual arrangements grounded in the voluminous body of technology
transfer and development arrangements and agreements associated with the
genomics revolution." Malinowski, supra note 11, at 58.
91. This may not be as astronomical as some studies have suggested. See
discussion supra notes 48 and 71.
92. See generally Ardais Corporation, http://www.ardais.com. Ardais uses
a licensing structure to cultivate its relationship with donor hospitals.
93. Fleischer, supra note 9.
94. Id. ("In February 2000, PXE International received good news from the
University of Hawaii. Pathobiologist Charles Boyd, who had been working with
the organization for nearly six years, stretching back to when he had been at
Rutgers University in New Jersey, had isolated the crucial gene.").
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chest of $150,000 "built up by swim-a-thons and bake sales," 95
PXE International was able to share the gene patent96 with the
university as well as negotiate favorable licensing and royalty
schemes, lowering costs of potential PXE medications.
97
PXE International's success in rallying an otherwise powerless
disease group may be attributed to savvy management of a closely
held biological and medical information portfolio, the ability to
directly steer efforts to advance PXE research milestones, as well
as sage legal advice which formed a foundation for these efforts.
98
Thus, the PXE model is most capable of endowing a formerly
disenfranchised disease group with a voice in the high-powered
world of pharmaceutical research and development.
When coupled with the biomedical transfer principles utilized
by the Beth Israel-Ardais method, which exchanges licenses to
access biobanking information for funding and research, the PXE
model may be able to empower many more. However, while some
orphan disease groups, like PXE International in the United States,
have already taken the initiative and made steps toward developing
biobanks, many others may require financial and organizational
assistance before they can reach such a point.
99
95. Id.
96. Gene patents may include "[a] purified DNA molecule isolated from its
natural environment [which] is a chemical compound and [thus] patentable ...."
Gregory P. Lekovic, Genetic Diagnosis and Intellectual Property Rights: A
Proposal to Amend "The Physical Immunity Statute", 4 Yale J. Health Pol'y, L
& Ethics 275, 281 (2004) (citing United States Patent and Trademark Office,
Dep't of Commerce, Utility Examination Guidelines, 66 FR 1092-02 (2002)).
Effectively, this "grants the right to exclude others, including the right to restrict
the licensing of the [gene] for non-economic purposes." Id.
97. Fleischer, supra note 9 ("[T]he group would only seek a deal that would
maximize patient access to a future PXE diagnostic test or PXE treatment--one
that provides a guarantee of access, a guaranteed supply, or a low cost.").
98. Id. Though now dissolved, Boston-based law firm Testa, Hurwitz &
Thibeault provided pro bono services to PXE International on a wide variety of
matters ranging from incorporation and "counsel about acquiring specimens for
their new bank" to filing gene patents.
99. Winickoff notes that the main difficulties in implementing PXE
International-like organizations are "practical." "First, it would require
significant initial investment. Second, without a government mandate, it is
unlikely that many of these organizations would emerge. In the ... PXE [case],
the pre-existence of both strong community identity and common goals
generated meaningful political representation and bargaining power."
Winickoff, supra note 10, at 226.
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Comparatively, neglected disease groups in developing
countries will experience significant difficulty establishing
biobanks because their environment is often impoverished and
steeped in political uncertainty. However, it is this paucity of
resources which makes creating attractive research tools like
biobanks so critical: biobanks may be the only way to draw
significant research attention to these commercially
disenfranchised disease populations.
A. Foundational Initiatives
Spurred by technology transfer programs and policy incentives
which encourage involvement by groups left out of the genomics
revolution, biobanks could prove an effective means to rally
disease groups overlooked by mainstream commercial and
academic interests.1°° However, fundamental questions remain:
issues of biological property rights, informed consent, and privacy
have been extensively discussed by commentators.
10 1
Property rights are especially important and, ideally, individual
donors would be granted some form of property interest in their
donated tissues. 1°2' This would validate the PXE International
approach which takes an ad hoc contractual property right
approach to biological samples and promises to grant PXE
sufferers a tangible benefit in exchange for the disclosure of their
medical information and donation of genetic samples. By settling
the legal issue, it would also allow the PXE International approach
to be applied to other orphan and neglected disease groups; without
a declared biological property right, efforts built on contractual
property rights, like PXE International, rest on uncertain ground. 103
100. Id. at 224 ("A big problem for rare-disease groups has traditionally been
the failure to attract researchers to study the disease .... The PXE strategy uses
the economic value of the tissues and organization's control over them both to
further particular research goals important to the community and to correct
market failures.").
101. See Malinowski, supra note 11, at 58-59; Winickoff, supra note 10, at
224; Donna M. Gitter, Ownership of Human Tissue: A Proposal for Federal
Recognition of Human Research Participants' Property Rights in Their
Biological Material, 61 Wash. & Lee L. Rev. 257 (2004).
102. See generally Gitter, supra note 101.
103. Professor Gitter notes that "the very existence of [PXE International's]
agreement invites consideration of how a court would rule if the researchers
were to bring a suit alleging that their contract with PXE International is void as
against public policy on the grounds that research participants cannot possess
property rights in their tissue. .. ." Id. at 264.
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Granting donors property rights to their biological material
paves the way for likeminded donors to organize and create their
own biobanks. Because ultimate control remains vested in the
donors, they would be the ones to decide which researchers-
academic or commercial-may have access to the valuable
information stored within their biobanks.' ° 4 This arrangement
allows donors to pool their samples and collaborate with academic
and commercial researchers to target their specific diseases such as
in the PXE International model.
Such initiatives to associate non-profit patient groups with
researchers are similar to technology transfer incentives enacted in
the 1980s and 1990s to drive the creation of academic and industry
partnerships "with the express intent of creating commercial
incentives to apply research financed by taxpayer dollars that
[were] trapped within filing cabinets in the nation's
universities." ° 5 While the close collaboration of these two sectors,
each pursuing divergent goals, has undoubtedly experienced
growing pains, 10 6 the end result has been beneficial to both
academia and industry. °7 Similarly, collaboration between non-
profit patient groups holding biobank assets, like PXE
International, with academic and commercial entities would not
only direct research efforts toward neglected and orphaned
diseases, but potentially achieve results neither could accomplish
alone.
104. Winickoff notes that with PXE International, "[ijnstead of waiting for
interested researchers to contact the group, the tissue trust allows donors to
create research projects that they deem to be beneficial. This, in turn increases
their economic bargaining power with the research entities involved."
Winickoff, supra note 10, at 225.
105. Malinowski, supra note 11, at 55.
106. Professor Malinowski notes that inexperience meant "[e]arly
agreements [between universities and industry] often were less than desirable
from a contemporary technology transfer perspective." These collaborations
have also created issues of overpatenting, conflicts of interest, impediments on
academic communication, and new restraints on the transfer of research
materials. Id. at 54-55.
107. Among the panoply of benefits includes greater productivity by
researchers "on scales of academic accomplishment that include academic
community service, teaching and publication," the commercial application of
research, and access to "proprietary enabling technologies" including
"bioinformatics capabilities and databases--essential for meaningful
participation in some of the most promising fields of contemporary genetic
science such as genomics... and proteomics." Id. at 55.
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But close cooperation, as seen in PXE International, stands as
the exception rather than the rule of biobank implementations
because the model hinges on granting donors a property interest in
their own tissues, an ownership interest which has been recognized
only in PXE International's own contractual provisions. For
instance, contractual terms used by biobanks in the United
Kingdom and Iceland divest donors of any ownership in their
genetic material. 0 8 Similarly, a California state decision, cited by
a subsequent Florida federal opinion, 0 9 have both declined to grant
biological property rights to patients.
In Moore v. Regents of the University of California,"0
physicians repeatedly withdrew tissue samples from the plaintiff
over a six year period, withdrawals which were ostensibly
"necessary and required for his health and well-being" when in fact
the physicians were secretly conducting research on the tissue and
hoping to "benefit financially and competitively."' l  The
California Supreme Court articulated several concerns in opposing
propertization of the plaintiff's tissues to support a claim of
conversion for the wrongful use of his tissue.
Primarily, the court asserted where "physicians act with
undisclosed motives that may affect their professional judgment,"
the plaintiffs claim was more solidly based "in the well-
recognized and long-standing principles of fiduciary duty and
informed consent. ' 2 Also, because conversion was a strict
liability tort, "it would impose liability on all those into whose
hands the cells come, whether or not the particular defendant
participated in, or knew of, the inadequate disclosures that violated
the patient's right to make an informed decision.""11 3 This was yet
another reason to rest the claim in fiduciary duty and informed
108. UK FAQ, supra note 33 ("UK Biobank will be the legal owner of the
database and the sample collection. Participants will not have property rights in
the samples and this will be explained at the outset before they consent to
participate."); deCODE Consent Form, supra note 34 ("If you decide to take part
in the study, you have to relinquish any claims to such financial gains .... ").
109. See Greenberg v. Miami Children's Hospital Research Institute, 264
F.Supp. 2d 1064 (S.D. Fla. 2003) (holding that plaintiffs did not have a property
interest in body tissue and genetic material donated for research to support a
claim of conversion; the donated material was used to patent a disease gene and
develop a commercial diagnostic test for that disease).
110. 793 P.2d 479 (Cal. 1990).
111. Id. at481.
112. Id. at 493.
113. Id. at 494.
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consent because those theories "protect the patient directly,
without punishing innocent parties .... ,114
Fears of strict liability "opening the floodgates" of litigation
may be resolved via legislative channels. In proposing
Congressional enactments of a "hybrid property rights/liability
model," commentators have suggested an additional element to
find conversion of body tissue: a "profit" factor which could
significantly rein in the fear of frivolous litigation:
In conversion cases, researchers' participants would be
entitled to compensation only if the researchers earned a
profit from commercializing their tissue .... Despite fears
about a proliferation of conversion actions, research
participants likely would file lawsuits only if they were
sufficiently aggrieved, and could expect a rather small
damage awards [sic] if their tissue were not unique [and
thus valuable to researchers] .115
Moreover, this refusal to propertize donor tissues may be a
position where law and policy have been outdistanced by science
and technology in the last fifteen years. To the Moore court and
the Greenberg court which followed it, the issues sub judice were
primarily not those of research and development, but rather
medical malpractice where informed consent and fiduciary duty
neatly addressed the rights of the parties. Thus, the respective
panels were perhaps unwilling to expand the conversion right of
action because it was not anticipated their opinions would
transcend medical malpractice.
It was unanticipated that commercial, academic, governmental,
and non-profit organizations, entire industries, could be founded on
the premise that genetic material and medical data not only has
some modicum of value, but also comprise a fundamental unit of
barter to be traded for more concrete assets such as capital and
research participation. Public participation is vital for these
ventures to succeed and lack of compensation for donors could
undermine this extensive trade, potentially creating the
"[w]idespread public perception that the current system is unfair[,
resulting in] not only... mistrust between patients and doctors and
a general decrease in research participation, but could also cause
an overall decline in ... support of such research."
'
"
16
Moreover, when these tissues play such a central role that they
are "just as indispensable in the research process as chemical
114. Id.
115. Gitter, supra note 101, at 340.
116. Id. at 298.
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reagents and other equipment used in scientific research, research
participants are no less deserving of compensation than the
suppliers of these materials . . . " thus, "considerations of equity
militate in favor of a system that compensates research participants
for their involvement.'"
117
A biobanking policy which addresses the needs of orphan and
neglected diseases must first reverse this international and
domestic precedent which fails to grant research participants a
property right in their own tissues before structured incentives,
drawn from orphan drug acts and technology transfer programs,
may be implemented to actively encourage such efforts. Further,
guidance as to international implementation and oversight in
developing these pro-biobanking policies may be provided by
bodies such as the World Health Organization, whose basic tenets
charge that "[t]he health of all peoples is fundamental to the
attainment of peace and security and is dependent upon the fullest
co-operation of individuals and States"'" and acknowledges that
"[u]nequal development in different countries in the promotion of
health and control of disease, especially communicable disease, is
a common danger."" 9
Grants of biological property rights with concomitant privacy
safeguards and informed consent protections form the substrate l
on which a charitable, non-profit biobanking policy can be built.' 21
Failing to grant donors a bargaining chip in the form of a
biological property right would make it difficult for organized
neglected and orphan disease sufferers to attract researchers; past
experiences have shown that in a global industry dominated by
Fortune 500 pharmaceutical giants and billion dollar research
117. Id. at 295, 298.
118. WHO Constitution, supra note 89.
119. Id.
120. "One of the main benefits flowing from patients groups' claims to
property rights in the tissue of their members is the potential for enhanced public
access to diagnostic tests and therapeutics for the treatment of disease, to the
extent that these groups demand some control over the licensing of the products
developed from such tissue." However, "it is clear that [patient advocacy
groups] do not provide the only or even the best means of protecting the rights
of research participants. For this reason, it is essential that the United States
Congress recognize the right of each individual research participant to claim a
property interest in his tissue." Gitter, supra note 101, at 319, 322.
121. Malinowski, supra note 11, at 59. The protection of donors, while
important even in conventional research, is heightened in the biobanking context
because of the wealth of personal information which may be extracted from
biological samples.
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budgets, such homegrown organizations have relatively little
political influence and even less financial capital.
B. Initiatives to Encourage Organization of Non-Profit Groups
Assuming the central issue of property rights in tissue may be
resolved, other policy issues must be decided before biobanking is
made available to neglected and orphaned disease groups.'
22
Policy must encourage disparate disease groups to coordinate and
form cohesive, disease-specific, non-profit organizations which
may recruit raise funds, and negotiate with potential
researchers. 12
Once organizations have been established, they may raise
funding and attract researchers by employing technology transfer
protocols similar to those used by the Beth Israel-Ardais
collaboration-that is, exchanging research expertise and funding
for access to their biobank assets. As the stewards of valuable
biological resources, directors of these organizations may negotiate
with interested academic or commercial entities to grant licenses
for access to the biobank. In exchange for these licenses allowing
them to closely examine extensive, correlated medical and genetic
data, 124 corporations will often provide monetary compensation as
in the Ardais model or research institutions may direct their work
as the patient group suggests as in the PXE International model. 125
Finally, some of these non-profit organizations may still be
unable to attract significant amounts of research interests. In such
cases, national and international initiatives similar to the Orphan
Drug Act may be required to stimulate research interest in these
diseases.
122. Malinowski, supra note 11.
123. Id.
124. Fleischer, supra note 9 ("Scientists by nature insist on access to a better
research tool--particularly one they have spotted in a competitor's hand").
125. "Technology transfer policy and regulation in biobanking must be
crafted in a manner that recognizes the potential for populations to become
sophisticated negotiators in biobanking and imposes necessary safeguards
without chilling the endeavor and related research." Malinowski, supra note 11,
at 59.
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1. Hearth and Home: Using the Louisiana Technology Park
Model to Provide Facilities and Advice to Aid Nascent
Biobanking Efforts
As Professor Malinowski has suggested, domestic and
international agencies could set up "pilot projects to facilitate
biobanking to accomplish defined objectives."6 Here, the defined
objective would be to develop biobanks which encourage research
of neglected and orphaned diseases. If these pilot projects proved
successful with a few initial patient groups, that is, they effectively
promote the development of biobanks while attracting research
attention, they may enjoy broader implementation.
The benefits conferred to patient groups by pilot projects could
be fairly elaborate and "actually help to organize participation and
negotiate biobanking arrangements ... thereby developing sound
contractual property rights for participants .... ,,127 Additionally,
pilot projects may need to provide entrepreneurial advice to startup
biobanks for fundraising as well as strategic negotiations with
established academic and commercial interests. Practical
considerations such as reliable freezer storage facilities for donated
tissues 128 and medical records' 29 as well as office space and
reliable communications systems would also be needed.
Such an arrangement may be similar to the Louisiana
Technology Park, 130 an "accelerator" program which "offers an
ongoing lifeline of support to nurture the early, critical phases of
young, start up technology companies ' 'q 3r whose logistical
demands are not dissimilar from those of patient groups seeking to
develop biobank assets. In fact, the Technology Park is host to
Celgene's Louisiana Stem Cell Repository. This repository
126. Id. at 60.
127. Id.
128. Fleischer, supra note 9. The Terrys initially used donated freezer space
at Tufts University but later moved to facilities at an Arizona laboratory to
house samples from 1,000 PXE patients. Id.
129. Id. ("[Miost of what's already collected doesn't impress researchers.
They want individual health histories and symptom descriptions too.").
130. See generally Louisiana Technology Park, http://www.latechpark.com/
(last visited Jan. 18, 2006).
131. Louisiana Technology Park, Three Year Review 6 (2004) [hereinafter
LTP Review].
132. Louisiana Technology Park, LTP Members, http://www. latechpark.com
/dynaweb/1001205/ei.cfm?M=112&SM=&SC=100000&W=C&P=N&S=10012
05 (last visited Jan. 18, 2006).
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stores tissues much the same way a biobank would- placental stem
cells are stored on site at 280 degrees below zero.13Y
Other services are also available to "foster, encourage and
promote success, at all levels for these companies, as well as to
guide and ensure their future success in every possible way,"'
34
such as subsidized office space, furniture, state-of-the-art
information technology, as well as access to "financi , legal,
marketing, public relations and Web design services."' 13 g All of
these incentives are pertinent to the development of nascent patient
groups; capable public relations advice and webpage authoring
expertise is needed for recruitment; 136 prudent financial advice is
needed to most effectively apply limited resources; and sound legal
advice is particularly important.
Legal advice is critical to efforts domestic and abroad,
especially in jurisdictions which do not recognize a donor's
property right in extracted tissue. In addition to the typical legal
transactions of a non-profit organization such as incorporation,
biobanks must also draft contractual provisions which allow third
parties access to biological assets while maintaining the
organization's interests in any potential breakthroughs. 137 Should
research become fruitful, subsequent negotiations with third-party
researchers would require savvy legal representation to ensure that
the organization's interests are protected. 1 38 Regardless of whether
the group is associated with an "accelerator" program, that so
much of a non-profit biobanks' assets are vested in ephemeral
intellectual property rights means capable legal advice is of
paramount concern. Legal counsel should be a significant factor
133. John Pope, Program Provides Stem Cell Access, New Orleans Times-
Picayune, July 16, 2003.
134. LTP Review, supra note 131.
135. Louisiana Technolgoy Park, Where Big Ideas Get Bigger,
http://www.latechpark.com/dynaweb/1001205/ei.cfm?M= 103&SM=&SC= 1000
00&W=C&P=N&S=1001205 (last visited Jan. 18, 2006).
136. See discussion infra Part II.B.2.
137. See generally Fleischer, supra note 9. Testa, Hurwitz & Thibeault
provided critical pro bono services to PXE International on a wide variety of
matters ranging from incorporation and "counsel about acquiring specimens for
their new bank" to filing gene patents. Id.
138. See Fleischer, supra note 9. PXE International and the University of
Hawaii initially had disagreements regarding the best way to share the PXE gene
patent as well as licensing provisions. Id.
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for government and international entities to consider when
promoting non-profit biobanking efforts.
139
The Louisiana Technology Park's supportive environment has
produced positive results. As of 2004, the Technology Park
housed eleven startup companies with seventy-seven employees
representing a payroll of $3.2 million. 4 0 These firms have also
raised $4.32 million in venture capital,' 4 ' and it is estimated that
"three companies will graduate each year."'142 The success of the
Technology Park, coupled with the presence of the Stem Cell
Repository as a tenant, suggests that similar assistance would be a
great help to patient groups looking to establish biobanks, raise
funds, and negotiate with academic and commercial entities.
2. Boots on the Ground: Organizing and Recruiting Donors
and Leaders
Apart from facilities, funding, and advice, policy must also
encourage patients to organize, a critical step to obtaining
collaboration with researchers as it empowers the disease group by
creating a body of potential donors and granting that body a
unified voice for research and fundraising purposes.
Governmental initiatives to encourage organization could be as
simple as disseminating information about the organization at
public facilities or as sophisticated as educating organizational
leaders to maximize research and fundraising opportunities.
However, the difficulties of organizing disease groups varies
considerably from region to region and from disease group to
disease group. Two factors may make organization of those
stricken with neglected diseases in the remote areas of Africa and
Asia significantly more onerous than organizing carriers of orphan
139. Matt Fleischer, Pitfalls of Pro Se Patenting, The American Lawyer,
June 2001, available at 6/2001 Am. Law. 87 ("One slip in PXE International's
impressive effort ... is the application they have given to researchers who want
access to their bank's blood and tissue. The document has a passage that
stipulates, 'Any patent shall be applied for jointly.' The group had not sent a
copy to patent counselor Patrick Waller of Boston-based Testa, Hurwitz &
Thibeault until this spring. Upon hearing the passage, he pronounced the terms
a little too pro se for his taste. 'You can't contract to make an invention,' he
observed. 'I'll need to take a look at that."').
140. LTP Review, supra note 131, at 28.
141. Id.
142. Id. at 29.
143. Winickoff, supra note 10, at 226.
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diseases in the United States: availability of telecommunications
infrastructure and political stability.
Developed telecommunications infrastructure is critical not
only because it allows patient groups access to conventional
telephony technologies but to the Internet as well, which plays a
significant role in this organizational process. As one
commentator noted:
[E]lectronic space remains a crucial force for new forms of
civic participation, especially in its public-access portion.
Non-commercial uses still dominate the Internet ... there
has been a proliferation of non-commercial uses and users.
Civil society, whether it be individuals or NGOs, is an
energetic presence in electronic space. From struggles
around human rights, the environment and workers' strikes
around the world to genuinely trivial pursuits, the Net has
emerged as a powerful medium for non-elites to
communicate, support each other's struggles and create the
equivalent of insider groups at scales going from the local
to the global.144
Powerful as it is, access to this enabling technology is far from
universal as this "[e]lectronic space is going to be far more present
in highly industrialized countries than in the less developed world;
and far more present for middle-class households in developed
countries than for poor households in those same countries.' 45
Political stability is also an important consideration for
development of these non-profit organizations. One commentator
has noted that while "political turmoil releases resources that can
be used to found new organizations," in the long run,
"entrepreneurs require political stability to engage in 'future-
oriented behavior.", 146  Some organizations may also require
international support which means "[t]he political stability of a
country, including economic and social stability, reduces the
uncertainty of potential investors, and therefore may increase the
144. Saskia Sassen, Towards a Sociology of Information Technology, 50
Current Sociology 365, at 368.
145. Id. at 367.
146. Douglas R. Wholey & Jack M. Brittain, Organizational Ecology:
Finding and Implications, 11 Acad. of Mgmt. Review 513, at 519 (citing H.E.
Aldrich, Organizations and Environments 166 (1979), available at
http://www.unc.edu/-healdric/Bokk/1979.html).
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level of [foreign direct investment] that flows into that country.' 147
Moreover, "investors clearly take into account the stability of the
investment environment before they commit their funds. 141
In the United States, these factors resolve favorably and tend to
ease the difficulties encountered by efforts which organize orphan
and neglected diseases. In fact, many orphan diseases groups have
already been organized to provide support and to disseminate
knowledge. 149 A modem telecommunications network facilitates
discussion between otherwise disparate members scattered about
the country. 150  A relatively stable political environment
encourages "future-oriented behavior" including the creation of
patient groups. Additionally, with a developed educational system,
leaders with business acumen willing to direct these organizations
may be found' 51 and those without leadership experience may
acquire these skills.1
52
In contrast, the challenges of organizing efforts in the areas
hardest hit by neglected diseases such as malaria seem
insurmountable. The world's highest malaria mortality rates are
found in African nations, such as the Democratic Republic of
Congo, Angola, Niger, and Sierra Leone, 53 which have been torn
by strife and poverty making them ideal breeding grounds for
epidemics.154 In such dire situations, it is uncertain whether any
147. David W. Loree & Stephen E. Guisinger, Policy and Nonpolicy
Determinants of U.S. Equity Foreign Direct Investment, 26 J. Int'l Business
Studies, No. 2, 288 (1995).
148. Id.
149. See The Genetic Alliance, www.geneticalliance.org, for an index of
organizations representing more than 800 genetic diseases, not all of which are
orphaned or neglected.
150. Id. The Genetic Alliance touts one of the major benefits of membership
being a robust network to connect stakeholders in the genetics community and
facilitate access to critical resources. Id.
151. Laker, supra note 4. Megan Crowley's father, John, held an MBA from
Harvard Business School.
152. Sharon and Patrick Terry did not have technical or business
backgrounds before they founded PXE International-they were "unlikely
players. When they started the PXE group, he was a construction manager; she
had a master's in religious studies and was teaching home-schooled students
part-time at a science museum." Fleischer, supra note 9.
153. WHO, The World Health Report 2004 148-55 (2004), available at
http://www.emro.who.int/PDF/whr2004en.pdf.
154. Angola has been torn apart by civil war for more than a quarter century
with seventy percent of its population considered below the poverty line. Since
1997, the Democratic People's Republic of Congo has undergone significant
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coordinated attempts to fight malaria by cultivating research
interest would meet with much success, especially where even the
prospect of day-to-day survival is uncertain.
However, it may be possible to "seed" stable and developed
countries in these regions with non-profit patient organizations.
155
Governments in these more stable countries could encourage the
development of domestic grassroots organizations by
disseminating recruitment information and by fostering leadership
and business acumen within patient groups.
As these organizations mature, they may be able to establish
toeholds in more volatile neighboring countries once the political
situation has stabilized. These toeholds could be as simple as
establishing branches in neighboring countries to recruit donors
and potential leaders to guide these offspring efforts, or as
sophisticated as lobbying governmental and business officials to
advance patient-group-friendly policy initiatives and legislation
encouraging the development of non-profit biobanks. Well-
established biobanking efforts may also provide financial aid, in
addition to governmental and international funds, to offspring
efforts in neighboring countries as well as organizational, financial,
and legal advice.
periods of civil war, tribal conflict, and rebel gang fighting as well, drawing in
neighboring states of Burundi, Rwanda, and Uganda. Similarly, civil war in
Sierra Leone has resulted in tens of thousands of deaths and over one-third of its
population displaced. Of the four countries with the highest malaria mortality
rates, Niger is currently the most politically stable, though it is crippled by
poverty. Niger ranks as one of the poorest countries in the world and suffers
from minimal government services and insufficient funds to develop its resource
base. Central Intelligence Agency ("CIA"), The World Factbook 2005 (2005),
available at http:www.cia.gov/cia/publications/ factbook/.
155. Niger's neighbor, Nigeria, currently holds a stable, civilian government
with expanding and improving telecommunications assets. Senegal-in the
same west African region as Sierra Leone-has a stable, multiparty democracy
with a well developed telecommunications infrastructure. Namibia-which
neighbors Angola-has a stable democracy as well as a "good" telephone
system. However, the central African nations surrounding the Democratic
Republic of the Congo have been marked by either political volatility,
inadequate infrastructure, or both. This poses a particularly untenable situation
for developing and organizing any non-profit biobanking organization. Id.
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C. Widening the Beaten Path: Orphan Drug Act Initiatives as a
Guide to Addressing Neglected Diseases
Incentives similar to those employed by orphan drug legislation
may also be brought to bear to encourage research of neglected
diseases abroad. These incentives may take the form of research
and development grants, tax breaks, and marketing exclusivity.
1. Show Me the Money: Domestic and International R&D
Grants
National and international initiatives may award grants to
commercial and academic researchers who work with a non-profit
biobanking organization and share their research priorities. Within
the United States, the National Institutes of Health and the Orphan
Drug Act may be appropriate financial sources.
Internationally, regional orphan drug enactments such as those
of the European Union and Japan, as well as the World Health
Organization in cooperation with the World Bank and the Office of
Economic Development may provide grants as well. 156 The Global
Fund, charged with fighting tuberculosis, malaria, and AIDS may
also be a significant resource. 57 These international contributions
will be most crucial in countries so impoverished they cannot
effectively address diseases independently. In these areas,
international efforts may serve as a proxy to national initiatives to
promote biobanking.
2. International Reciprocity and the Beijing Tea Party: No
Taxation without Commercialization
Tax breaks to researchers may be administered with relative
ease if both the targeted disease and the research are located in the
same country. However, in international scenarios where, for
instance, a French researcher assisted a biobanking organization
located in Nigeria, international agreements establishing a system
of reciprocity in granting tax breaks may need to be arranged.
While there is no direct precedent for such an international tax
156. Malinowski, supra note 11, at 60.
157. See generally The Global Fund to Fight AIDS, Tuberculosis, and
Malaria, http://www.theglobalfund.org.
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break structure, a somewhat similar system has been adopted in the
People's Republic of China ("China"). 158
In assessing China's attitudes toward altruistic investments,
that is, those investments which rely "on the recipient's increased
well-being and [do] not seek to profit at another's expense ...
[thus] rescu[ing] those the market economy leaves behind,"' 15 9 it
has been noted that:
[T]he Chinese State Administration of Taxation (SAT) has
held in an administrative ruling that foreign non-profit
organizations that are recognized as tax exempt in their
home country may be granted tax exempt status in China
solely on the basis of their home country tax exempt[ion].
At least in theory, then, China has a formal and broadly
stated mutual recognition provision in its tax laws.
60
This structure is not directly analogous with the system of
international tax breaks we consider here. For instance, the
Chinese structure applies to non-profit organizations working both
in-country and on foreign soil rather than for-profit industries
conducting altruistic R&D in cooperation with non-profit efforts
abroad. However, the bare underpinnings are present: a system of
international reciprocity granting tax credit for altruistic works.
Implementation of such a system may take cues from the Chinese
arrangement, adding flexibility to account for for-profit
corporations pursuing altruistic research rather than only non-
profits and applying the structure broadly to encompass efforts in
many countries.
3. The Precarious Balance of Exclusivity
One of the most valuable Orphan Drug Act incentives-limited
market exclusivity of seven years for any drugs which are
developed-has also proven the most controversial and must be
implemented carefully because it may act counter to policy. 16 For
158. See generally Darryll K. Jones, The Neglected Role of International
Altruistic Investment in the Chinese Transition Economy, 36 Geo. Wash. Int'l L.
Rev. 71 (2004).
159. Id. at 72, 73.
160. Id. at 112-13.
161. Market exclusivity drives up the cost of drugs to, perhaps prohibitively,
high rates. See Robert A. Bohrer & John T. Prince, A Tale of Two Proteins: The
FDA's Uncertain Interpretation of the Orphan Drug Act, 12 Harv. J.L. & Tech.
365, 382 (1999) ("[Clritics decry the fact that market exclusivity leads to higher
prices that prohibit access to the drug."). These windfalls are for not
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diseases such as malaria, tuberculosis, and AIDS, drugs which
arise from these cooperative efforts should not be monopolized
simply because the disease is too rampant and the need for
effective treatments too dire. However, grants of market
exclusivity make it easier for commercial, if not academic,
interests to justify investing in the costly research and development
process. 16 2 Indeed, the market exclusivity provision is the most
contentious aspect of the, otherwise universally lauded, Orphan
Drug Act; critics have charged it drives up costs for medicines and
grants pharmaceuticals an opportunity to reap a windfall 163 while
its proponents assert that, without exclusivity, it would be difficult
if not impossible for pharmaceuticals to recoup their research
investments. 164
This delicate balancing of interests could be resolved with
gradual implementation of market exclusivity. Medicines may be
marketed exclusively in areas where a disease is common, but not
widespread, and where a stable local economy may offset any
potentially heightened costs resulting from the grant of exclusivity.
Using malaria as an example, Nigeria may be an instance where
the balancing of corporate interests and humanitarian efforts
insignificant amounts. As one commentator notes, a company operating under
the exclusivity provision "recovered ten times its cost of producing a growth
hormone for pituitary deficiencies, earning the company $580 million on the
drug alone in its first five years of exclusive marketing." Ester Chang, Fitting a
Square Peg Into a Round Hole? Imposing Informed Consent and Post-Trial
Obligations on United States Sponsored Clinical Trials in Developing
Countries, 11 S. Cal. Interdisc. L.J. 339, 357 n.151 (2002).
162. Richard A. Merrill, The Architecture of Government Regulation of
Medical Products, 82 Va. L. Rev. 1753, 1791 n.119 (1996) ("[T]here is general
agreement that the Orphan Drug Act produced the economic incentives needed
to promote development of drugs for rare diseases."); John Henkel, Orphan
Products: New Hope for People with Rare Disorders, FDA Consumer (January
1995), available at http://www.fda.gov/fdac/special/newdrug/orphan.html
("[E]xclusivity gives sponsors legal protection against introduction of an
identical competing product for seven years. This 'shelter' is critical to keeping
many companies interested in orphans . . . . 'Large firms need exclusivity to
convince management to invest capital . . . [a]nd small-to-medium-sized
companies need it to ensure stockholders that the product won't be infringed
upon by competitors.' . . . These firms can gain a 'quasi-patent' under the
Orphan Drug Act's marketing exclusivity provision. Without this protection,
many of these companies probably would not pursue orphans.").
163. Bohrer & Prince, supra note 161; Chang, supra note 161.
164. Merrill, supra note 162.
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resolves in favor of exclusivity. 165 Conversely, exclusivity should
be denied in areas where the disease situation is pandemic and the
local economy is depressed or nonexistent, such as in Niger.
Often, these are the areas which need medicines the most. As the
prevalence of disease abates and the economic climate stabilizes,
market exclusivity restrictions may be gradually implemented in
these formerly troubled areas.
However, this gradual implementation of market exclusivity
raises many critical issues: What socio-economic conditions
should be examined in deciding whether or not to implement
market exclusivity? Must market exclusivity be manifested as a
brightline, binary proposition or may it be implemented as a
gradient-complete exclusivity for more prosperous nations, less
complete for less prosperous nations-which better balances
countervailing interests? How may a country regulate and enforce
market exclusivity in regions where national borders may be
porous and difficult to police? May humanitarian considerations
justify the potential for heightened prices resulting from market
exclusivity in more prosperous countries, which will have already
shouldered much of the burden in establishing biobanks and
encouraging drug development by enacting initiatives such as tax
breaks and grants? If a troubled nation fails to stabilize within the
period of market exclusivity, would the more prosperous nations
be forced to absorb all the potential pricing disparities? How
might market exclusivity of treatments and cures, produced by
international cooperative efforts, be implemented under the
requirements of globalization treaties such as the General
Agreement on Tariffs and Trade (GATT) and Trade-Related
Aspects of Intellectual Property Rights (TRIPS)? How may
commercially-oriented interests be prevented from abusing market
exclusivity provisions to obtain windfalls at the expense of patient
health? However these issues are resolved, it is clear that if
commercial and humanitarian interests are to be protected, market
exclusivity for products developed from biobanking efforts cannot
be avoided.
A wide variety of policy initiatives may be implemented to
encourage the development of biobanks in all its stages, from the
nascent phase to implementation, and active research and
development. If incentives are skillfully administered to
promising, self-sustaining biobanking efforts, it is more likely that
patients stricken with previously orphaned and neglected diseases
165. See sources cited supra notes 153-54. Nigeria is in a far more favorable
politico-economic situation relative to its neighbor, Niger.
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will be able to gain a valuable voice and obtain research and
funding with a minimum of governmental expenditure.
CONCLUSION
It is clear that orphaned and neglected disease groups are in
dire need of assistance though some patient groups may be better
off than others due to self-initiated fundraising and organization.
Though still years away from a cure, Megan Crowley's
perseverance in fighting Pompe disease and her parents' persistent
efforts to raise awareness and arouse research interests embodies
much of the unfaltering determination and entrepreneurial finesse
required for widespread non-profit biobanking to succeed. These
organizations must succeed. For every Pompe disease which has
found a voice, for every PXE which has found a champion, dozens
of other disease groups and tens of millions of other patients have
been left behind. These multitudes have been abandoned by
commercial interests which cannot justify the stratospheric
research and development costs for diseases groups too minuscule
or impoverished to recoup their expenditures as well as by public
institutions which, all too often, set their research goals alongside
those of commercial entities.
Biobanking initiatives, which have made our very biological
material a valuable asset, has the potential to equalize this
disparity. By encouraging grassroots organization and by vesting
in donors a valuable property right in their own biological samples,
millions of disenfranchised patients around the globe may be
granted a voice in fundraising, and in directing research and
development efforts. Once these efforts are realized, those who
suffered in silence may finally be granted some access to the
towers of commerce and the halls of academia from which they
have been barred.
Brian Su*
* I am deeply grateful to Prof. Michael Malinowski for his invaluable
guidance and assistance in the development of this article. Also, much thanks to
my family and friends for their support.
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